BioTheryX Stock
BioTheryX is a clinical-stage biopharmaceutical company that focuses on the development of therapies for hematological malignancies.
Sign up today and learn more about BioTheryX Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About BioTheryX Stock
BioTheryX focuses on the development of therapies for hematological malignancies. It intends to leverage its extensive experience and proven commercial success to deliver efficacious therapies to patients with unmet medical needs more quickly and less expensively than the biomedical industry traditionally can and does. To do so, they are exploiting enhanced biology-driven models to identify effective core molecules that can be rapidly exploited using focused and prioritized chemistry approaches coupled with clinically proven translational approaches targeted for cancer and immune dysfunction. The company was founded in 2007 and is headquartered in Chappaqua, New York.
Funding History
June 2014 | $1.0M |
---|---|
September 2014 | $150K |
May 2015 | $500K |
July 2020 | $35.0M |
May 2021 | $18.0M |
May 2021 | $92.0M |
Management
Chief Business Officer
Sahm Nasseri
Chief Financial Officer
Jeff Caravella
Co-Founder, President & Board Member
Lawrence Zaslow
Co-Founder, Chief Development Officer & Chairman & Owner
David Stirling
Board Member
Robert Platek
Chief Executive Officer
Philippe Drouet
Press
bioworld - Dec, 11 2023
Biotheryx discloses new CDK protein degradersbioworld - Oct, 17 2023
Biotheryx patents new SOS1 degradation inducers for cancerbioworld - Apr, 8 2023
Biotheryx and Incyte collaborate on targeted protein degraders for novel oncology targetsendpts - Apr, 7 2023
Incyte links arms with tiny Biotheryx for protein degrader deal, targeting cancerprnewswire - Aug, 24 2022
Biotheryx Announces Appointment of Tracy Lawhon as Chief Development Officer